Enbrel

Type: Product
Name: Enbrel
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Pfizer Earnings May Miss As Revenues Fall Due To Patent Expiry

Pfizer’s earnings may be below expectations, as revenues decline due to patent expiry of major drugs that caused cheaper generics to flood the marketClick Ticker to See live coveragePfizer ( PFE ) is expected to announce earnings for the second quarter ... [Published Bidness Etc - 2 hours ago]
Entities: Pfizer Inc, Drugs, Patent
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 Investigational Etanercept Biosimilar In Chronic Plaque Psoriasis RaPsOdy

By a News Reporter-Staff News Editor at Biotech Business Week Coherus BioSciences , Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel), in chronic plaque psoriasis (the RaPsOdy trial). This announcement ... [Published Pharmacy Choice - 5 hours ago]
Entities: Enbrel, Psoriasis, Phase III
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Amgen’s Second-Quarter Earnings Look Strong

at 6:28 am ESTClick Ticker to See live coverageAmgen, Inc. ( AMGN ) will announce earnings for the second quarter of its 2014 fiscal year (2QFY14) on July 29 after markets close. Its earnings per share are expected to register a 12.4% increase year-over-year ... [Published Bidness Etc - 6 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Novartis announces NEJM publication of two pivotal Phase III secukinumab studies

Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary endpoints ... [Published Drugs.com - 8 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Biologic treatments for RA carry similar infection risk

The risk of hospitalized bacterial infections in older rheumatoid arthritis patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care ... [Published Medical Xpress - 10 hours ago]
First reported Jul 26 2014 - Updated Jul 27 2014 - 1 reports

FDA will consider approval of biologic drug for first time

Americans are a small step closer to accessing less-expensive specialty drugs known as biologics.The Food and Drug Administration for the first time accepted an application for the approval of a copycat “generic” version of the brand name drug Neupogen, ... [Published PBS - Jul 26 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Doctor Criticized For His Questionable 'Treatment' For Alzheimer's Patients Files SLAPP Suit To Silence Critic

Dr. Edward Tobinick was the subject of an LA Times article in 2013 -- I'd link to it, but it appears to have disappeared, though I don't know why -- which highlighted his (apparently now discontinued) practice of prescribing a particular drug, Enbrel, ... [Published Techdirt - Jul 26 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Humira Still Key to AbbVie

AbbVie ( NYSE: ABBV     ) markets the planet's top-selling biotechnology drug, and the company's second-quarter results show no signs that Humira's sales pace is slowing.That's good news for AbbVie, but investors are right to wonder whether the company's ... [Published Motley Fool Discussion Boards - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis...

Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patientsBy a News Reporter-Staff News Editor at Biotech Week Novartis announced that The New England ... [Published Pharmacy Choice - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Global cell culture market to grow at 10.27% CAGR by 2018

The global cell culture market will grow at a CAGR of 10.27 percent over the period of 2013-2018, predict analysts in a recently released report . The major driver behind this growth is the increased demand for biopharmaceuticals, particularly with growth ... [Published Terrapinn - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 3 reports

Legal thuggery directed at Steve Novella and Science-Based Medicine [Respectful Insolence]

If there’s one characteristic of supporters of dubious medicine, it’s that they hate criticism. Whereas your average skeptic might not like criticism—sensitivity to criticism being a human trait and all—science- and evidence-based criticism tends to ... [Published ScienceBlogs : Combined Feed - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Much interest in stroke treatment

Dave Griffin.A Dunedin man believed to be the first New Zealander toundergo innovative stroke therapy in the United States may havebecome a trailblazer.Brenda Griffin said her phone and social media page had been''red hot'' since the Otago Daily Times ... [Published Otago Daily Times - Jul 21 2014]

Quotes

"With two late-stage trials now underway in partnership with Coherus, we are advancing our collective goals to develop and deliver high quality biologic alternatives that address patient needs" saidLudwig Hantson, Ph D , president of Baxter BioScience
...te-to-severe symptoms who need new options," said Christi Shaw, President, Novartis Pharmaceuticals Corporation and President, Novartis Corporation. "The publication of the Phase III data in NEJM validates the significance of the studies and draws attention to the major unmet need in this disease. Novartis will continue working with investigators and the FDA to bring secukinumab to patients as soon as possible."
"In older, predominantly male U S veterans with RA, the risk of hospitalized bacterial infections associated with rituximab or abatacept was similar to etanercept" the authors write
On top of those threats, Novartis " Sandoz is already developing a biosimilar generic version of Humira it hopes to launch once Humira's patent expires. If Novartis is successful, Humira's sales will likely fall more quickly after it loses exclusivity."

More Content

All (199) | News (159) | Reports (0) | Blogs (36) | Audio/Video (0) | Fact Sheets (3) | Press Releases (1)
sort by: Date | Relevance
Pfizer Earnings May Miss As Revenues Fall Due T... [Published Bidness Etc - 2 hours ago]
Coherus Announces Initiation Of Phase 3 Trial O... [Published Pharmacy Choice - 5 hours ago]
Amgen’s Second-Quarter Earnings Look Strong [Published Bidness Etc - 6 hours ago]
Novartis announces NEJM publication of two pivo... [Published Drugs.com - 8 hours ago]
Biologic treatments for RA carry similar infect... [Published Medical Xpress - 10 hours ago]
FDA will consider approval of biologic drug for... [Published PBS - Jul 26 2014]
Doctor Criticized For His Questionable 'Treatme... [Published Techdirt - Jul 26 2014]
Humira Still Key to AbbVie [Published Motley Fool Discussion Boards - Jul 25 2014]
Biological Drugs Market: Global Industry Analys... [Published PRWeb - Jul 25 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Jul 25 2014]
FDA opens the door for a Novartis biosimilar of... [Published FierceBiotech - Jul 24 2014]
Protalix BioTherapeutics Names Shlomo Yanai as ... [Published Stock Nod - Jul 24 2014]
Biogen Idec Beats And Raises: Reassessing Its P... [Published Seeking Alpha - Jul 23 2014]
Reports Outline Cancer Therapy Study Findings f... [Published 4 Traders - Jul 23 2014]
Global cell culture market to grow at 10.27% CA... [Published Terrapinn - Jul 23 2014]
Legal thuggery directed at Steve Novella and Sc... [Published ScienceBlogs : Combined Feed - Jul 23 2014]
Another Lawsuit To Suppress Legitimate Criticis... [Published NeuroLogica Blog - Jul 23 2014]
Another Lawsuit To Suppress Legitimate Criticis... [Published Science-Based Medicine - Jul 23 2014]
Novartis announces NEJM publication of two pivo... [Published Pharmacy Choice - Jul 23 2014]
DAILY NEWSFLASH: What's happening in your world... [Published Gympie Times - Jul 22 2014]
Reverse stroke treatment has family crying tear... [Published Gatton Star - Jul 22 2014]
Global Biosimilar/Follow-on Biologic market exp... [Published Terrapinn - Jul 22 2014]
New psoriasis drug shows potential [Published Science Daily - Jul 21 2014]
Much interest in stroke treatment [Published Otago Daily Times - Jul 21 2014]
CEL-SCI Receives $225,000 NIH Research Grant to... [Published Terrapinn - Jul 21 2014]
Common arthritis drug stopped Alzheimer's in it... [Published McKnight's Long Term Care News - Jul 21 2014]
Mom has RA [Published HealthBoards - Jul 21 2014]
Alzheimer's Progression Slowed Down by Arthriti... [Published Softpedia - Jul 19 2014]
Satisfaction of treatment with biologics is hig... [Published British Journal of Dermatology - Jul 18 2014]
Melanoma associated with tumour necrosis factor... [Published British Journal of Dermatology - Jul 18 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Doctor Criticized For His Questionable 'Treatme... [Published Techdirt - Jul 26 2014]
Dr. Edward Tobinick was the subject of an LA Times article in 2013 -- I'd link to it, but it appears to have disappeared, though I don't know why -- which highlighted his (apparently now discontinued) practice of prescribing a particular drug, Enbrel, ...
Legal thuggery directed at Steve Novella and Sc... [Published ScienceBlogs : Combined Feed - Jul 23 2014]
If there’s one characteristic of supporters of dubious medicine, it’s that they hate criticism. Whereas your average skeptic might not like criticism—sensitivity to criticism being a human trait and all—science- and evidence-based criticism tends to ...
Another Lawsuit To Suppress Legitimate Criticis... [Published NeuroLogica Blog - Jul 23 2014]
I suppose it was inevitable. In fact, I’m a bit surprised it took this long. SGU Productions, the Society for Science-based medicine, and I are being sued for an article that I wrote in May of 2013 on Science-Based Medicine . My SBM piece, which was ...
Another Lawsuit To Suppress Legitimate Criticis... [Published Science-Based Medicine - Jul 23 2014]
I suppose it was inevitable. In fact, I’m a bit surprised it took this long. SGU Productions, the Society for Science-based medicine, and I are being sued for an article that I wrote in May of 2013 on Science-Based Medicine . My SBM piece, which was ...
Mom has RA [Published HealthBoards - Jul 21 2014]
So my mom was diagnosed with rheumatoid arthritis about 6 years ago or so. She is on enbrel injections, methotrexate, tramadol as needed (pain killer) and i think folic acid.She experiences drenching night sweats, sometimes her one eye gets red and watery/itchy ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Coherus maakt bekend dat CHS-0214 (Proposed Eta... [Published PR Newswire - Oct 29 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.